Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 206 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: NAC Clear all

Conditions: Cornelia de Lange Syndrome
Interventions: N-acetyl cysteine, Placebo; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 13 Years to 35 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Long-term Effects Secondary to Cancer Therapy in Children
Interventions: filgrastim, acetylcysteine, carboplatin, cyclophosphamide, etoposide phosphate, mannitol, sodium thiosulfate; Biological · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 1 Year to 18 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Neuropathic Pain
Interventions: N-acetyl-l-cysteine; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Alcoholism
Interventions: N-acetylcysteine + high-dose naltrexone (150 mg), High-dose naltrexone (150 mg) alone, Low-dose naltrexone (50 mg) alone; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 2
States / cities: West Haven, Connecticut • Minneapolis, Minnesota

Conditions: Glioblastoma, GBM
Interventions: Acetadote; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: Rifaximin, N-acetylcysteine, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
Interventions: Not listed
Lead sponsor: Personalis Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 14
States / cities: Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 11 more

Conditions: Allergic Rhinitis
Interventions: ASP-1001 nasal spray, Placebo for ASP-1001; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Days to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Fibromyalgia
Interventions: minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo, Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily); Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Retinitis Pigmentosa
Interventions: NAC effervescent tablets; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COVID, Sars-CoV2, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Oxidative Stress
Interventions: N-acetylcysteine; Drug
Lead sponsor: Cambridge Health Alliance; Other
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Cambridge, Massachusetts • Everett, Massachusetts • Somerville, Massachusetts

Conditions: Onychophagia
Interventions: N-Acetylcysteine (NAC), Placebo; Drug · Other
Lead sponsor: Kevin Gray, MD; Other
Eligibility: 18 Years to 30 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Interventions: N-acetylcysteine, Oral acetylcysteine; Drug
Lead sponsor: Center for Veterans Research and Education; Other
Eligibility: 40 Years to 85 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Autism Spectrum Disorder
Interventions: N-acetylcysteine; Drug
Lead sponsor: Stanford University; Other
Eligibility: 3 Years to 13 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Stanford, California

Conditions: Squamous Cell Carcinoma of the Head and Neck, Oropharynx, Human Papillomavirus Viruses, Drug Therapy, Cancer Vaccine
Interventions: Docetaxel, Cisplatin, PRGN-2009; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Urothelial Cancer, Bladder Cancer
Interventions: Neoadjuvant Cisplatin and Gemcitabine; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Rochester, New York • Portland, Oregon

Conditions: Acute Respiratory Distress Syndrome
Interventions: N-acetyl cysteine; Drug
Lead sponsor: Prisma Health-Midlands; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: End Stage Liver Failure
Interventions: N-acetylcysteine; Drug
Lead sponsor: Ibtesam Hilmi; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Gulf War Syndrome
Interventions: N-Acetyl Cysteine, Placebo; Drug
Lead sponsor: Nova Southeastern University; Other
Eligibility: 47 Years to 70 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Palo Alto, California • Fort Lauderdale, Florida • Boston, Massachusetts + 4 more

Conditions: Cocaine Dependence
Interventions: N-Acetylcysteine, Matching Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions: N-acetyl cysteine, Placebo; Drug
Lead sponsor: Emmanuelle Waubant, MD PhD; Other
Eligibility: 40 Years to 70 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Alcohol Use Disorder
Interventions: N-acetylcysteine, Placebo oral capsule; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 13 Years to 25 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Cannabis Dependence
Interventions: N-Acetylcysteine, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 50 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Los Angeles, California • New Haven, Connecticut • Lexington, Kentucky + 3 more

Conditions: Aneurysmal Subarachnoid Hemorrhage, Cerebral Vasospasm
Interventions: Placebos for acetaminophen and N-acetylcysteine, APAP 1 gm every 6 hours and N-acetylcysteine placebo, NAC IV infusion at 0.5 gm hourly and APAP placebo, APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly, APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 20 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain

N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence

Imaging Acetadote Metabolism in Glioblastoma

Efficacy and Safety of Rifaximin With NAC in IBS-D

CtDNA Based MRD Testing for NAC Monitoring in TNBC

Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)

The Effect of Minocycline and N-acetylcysteine for the Treatment of Fibromyalgia

FIGHT-RP 1 Extension Study

Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease

Use of N-Acetylcysteine (NAC) in Fingernail Biting

N-Acetylcysteine for Patients With COPD and ChronicBronchitis

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)

N-Acetyl-cysteine in Early Acute Respiratory Distress Syndrome

N-acetylcysteine in Liver Transplantation

GWICTIC: NAC Mechanistic Study in Gulf War Veterans

Effectiveness of N-Acetylcysteine (NAC) in Treating Cocaine Dependent Individuals - 1

Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis

N-Acetylcysteine for Adolescent Alcohol Use Disorder

Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment

Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm